Novartis' Remibrutinib Gains FDA Approval for Chronic Spontaneous Urticaria
TL;DR
Novartis received FDA approval for Rhapsido (remibrutinib), the first oral BTK inhibitor for treating adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite antihistamines, offering a new, fast-acting, and safe treatment option without the need for injections or lab monitoring.
Topics:businesshealthcare#chronic-spontaneous-urticaria#fda-approval#healthcare#novartis#remibrutinib#rhapsido
- Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU) Novartis
- FDA approves Novartis’ BTK inhibitor for chronic hives Endpoints News
- Novartis' skin disease drug gets US approval Reuters
- Downtown Helena turns pink for Breast Cancer Awareness Month Yahoo
- Discussing Remibrutinib Following FDA Approval for CSU, With Adam Friedman, MD HCPLive
Want the full story? Read the original reporting
Read on Novartis